Transaction in Own Shares

/**/

RNS Number : 3580N CVS Group plc 02 January 2026  

02 January 2026   CVS GROUP plc ("CVS" or the "Company" and, together with its subsidiaries, the "Group") Transaction in own shares   CVS announces that on 31 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").  

Date of purchase:

31/12/2025

Aggregate number of Ordinary Shares purchased:

4,554

Lowest price paid per share (GBp):

1,266.00

Highest price paid per share (GBp):

1,278.00

Volume weighted average price paid per share (GBp):

1,273.59



CVS intends to cancel all of the purchased Ordinary Shares.   Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,706,719 Ordinary Shares in issue and holds no Ordinary Shares in treasury.   The total number of voting rights in CVS is therefore 70,706,719 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.   Since the commencement of the Share Buyback Programme, the Company has repurchased 1,034,064 Ordinary Shares in aggregate at a weighted average price of 1,221.27 pence per share.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.   Individual transactions:  

Number of Ordinary Shares purchased

Transaction price (GBp share)

Time of transaction (UK Time)

Transaction reference number

Trading Venue

 





70

1266

31/12/2025 10:08:21

1361977762912325

XLON



44

1266

31/12/2025 10:26:31

1361977762912807

XLON



1

1266

31/12/2025 10:26:31

1361977762912808

XLON



10

1266

31/12/2025 10:26:31

1361977762912809

XLON



6

1266

31/12/2025 10:26:31

1361977762912810

XLON



19

1266

31/12/2025 10:26:31

1361977762912811

XLON



6

1266

31/12/2025 10:26:32

1361977762912812

XLON



281

1268

31/12/2025 10:39:29

1361977762913259

XLON



25

1266

31/12/2025 10:39:29

1361977762913260

XLON



106

1268

31/12/2025 10:39:29

1361977762913261

XLON



111

1266

31/12/2025 10:39:32

1361977762913262

XLON



32

1268

31/12/2025 10:50:04

1361977762913570

XLON



9

1268

31/12/2025 10:50:04

1361977762913571

XLON



11

1268

31/12/2025 10:50:04

1361977762913572

XLON



276

1272

31/12/2025 10:59:24

1361977762913854

XLON



96

1272

31/12/2025 10:59:24

1361977762913857

XLON



85

1268

31/12/2025 11:14:47

1361977762914340

XLON



204

1276

31/12/2025 11:23:24

1361977762914655

XLON



191

1274

31/12/2025 11:24:40

1361977762914690

XLON



40

1276

31/12/2025 11:29:31

1361977762914855

XLON



115

1276

31/12/2025 11:29:31

1361977762914856

XLON



483

1270

31/12/2025 11:43:40

1361977762915573

XLON



553

1276

31/12/2025 11:50:04

1361977762915810

XLON



560

1276

31/12/2025 11:50:04

1361977762915813

XLON



78

1276

31/12/2025 11:56:01

1361977762916089

XLON



154

1276

31/12/2025 12:01:30

1361977762916311

XLON



231

1276

31/12/2025 12:03:15

1361977762916359

XLON



135

1276

31/12/2025 12:03:15

1361977762916360

XLON



178

1276

31/12/2025 12:05:10

1361977762916425

XLON



158

1278

31/12/2025 12:11:22

1361977762916728

XLON



286

1278

31/12/2025 12:15:34

1361977762916940

XLON



    Contacts CVS Group plc                                                                                                                                                 via Camarco Richard Fairman, CEO Robin Alfonso, CFO Paul Higgs, Chief Veterinary Officer Charlotte Page, Head of Investor Relations   Peel Hunt LLP (Nominated Adviser & Joint Broker)                                                                                 +44 (0)20 7418 8900 Christopher Golden / James Steel / Andrew Clark   Berenberg (Joint Broker)                                                                                                                             +44 (0)20 3207 7800 Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing   Camarco (Financial PR)                                                                                                                             cvsg@camarco.co.uk Ginny Pulbrook                                                                                                                                                +44 (0)7961 315 138 Letaba Rimell Tilly Butcher   About CVS Group plc (www.cvsukltd.co.uk)   CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.   The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").   The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.    

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  POSWPGGUPUPAGCG